Natalie is Chief Executive Officer (CEO) of Third Harmonic Bio. She has more than 20 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas.
Prior to Third Harmonic Bio, Natalie served as President and CEO of Audentes, an Astellas company. She joined the company as Senior Vice President (SVP) and Chief Operating Officer (COO) in August 2015 and was subsequently promoted to President and COO in May 2018, and then to President and CEO in January 2020. Prior to joining Audentes, Natalie served as SVP, Corporate Development at Hyperion Therapeutics, Inc. (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.
Natalie holds an A.B. in human biology from Stanford University and an M.A. in molecular, cellular, and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow.
What is Natalie C. Holles' net worth?
The estimated net worth of Natalie C. Holles is at least $6.56 million as of April 11th, 2024. Holles owns 1,218,836 shares of Third Harmonic Bio stock worth more than $6,557,338 as of December 4th. This net worth evaluation does not reflect any other investments that Holles may own. Learn More about Natalie C. Holles' net worth.
How do I contact Natalie C. Holles?
Has Natalie C. Holles been buying or selling shares of Third Harmonic Bio?
Natalie C. Holles has not been actively trading shares of Third Harmonic Bio in the last ninety days. Most recently, Natalie C. Holles sold 13,558 shares of the business's stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $12.19, for a transaction totalling $165,272.02. Following the completion of the sale, the chief executive officer now directly owns 1,218,836 shares of the company's stock, valued at $14,857,610.84. Learn More on Natalie C. Holles' trading history.
Who are Third Harmonic Bio's active insiders?
